Amarin Corporation

Amarin Corporation EBITDA per Employee

The EBITDA per Employee of Amarin Corporation (AMRN) as of Oct 28, 2026 is -174,262.50 USD. In the previous year, EBITDA per Employee was -1.15 M USD — a change of -84.81% (higher).

EBITDA per Employee

-174,262.50USD

YoY

-84.81%

Last updated:

EBITDA per Employee of Amarin Corporation is 2025 -174,262.50 USD. EBITDA per Employee of Amarin Corporation was 2024 -1.15 M USD. It decreases by -84.81% higher compared to the previous year.

The Amarin Corporation EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
-1.35 M USD
Jan 1, 2019
-303,487.50 USD
Jan 1, 2020
-245,687.50 USD
Jan 1, 2021
131,275.00 USD
Jan 1, 2022
-1.32 M USD
Jan 1, 2023
-707,700.00 USD
Jan 1, 2024
-1.15 M USD
Jan 1, 2025
-174,262.50 USD
The Amarin Corporation EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-174,262.50USD-84.81%
-1.15 MUSD+62.14%
-707,700.00USD-46.52%
-1.32 MUSD-1,108.08%
131,275.00USD-153.43%
-245,687.50USD-19.05%
-303,487.50USD-77.49%
-1.35 MUSD+134.11%
-575,862.50USD-20.49%
-724,225.00USD-41.01%
-1.23 MUSD+2.36%
-1.20 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

EBITDA per Employee of Amarin Corporation is -174,262.50 USD in 2025.

EBITDA per Employee of Amarin Corporation changed from -1.15 M USD to -174,262.50 USD, representing a -84.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Amarin Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Amarin Corporation

All Key Metrics — Amarin Corporation